

Cover Story
Guest Editorial
Over and over again, I’ve seen the same missteps, clumsy excuses, and faulty logic during sponsor presentations to the FDA Oncologic Drugs Advisory Committee, repeated as if part of a tragic, regulatory update to the movie Groundhog Day.
In Brief


Clinical Roundup


Drugs & Targets


Trending Stories
- Richard Pazdur left FDA to avoid being part of “the destruction of the American medical system”
- Harvey Risch, critic of COVID-19 response, tapped by White House to serve as chair of the President’s Cancer Panel
- Brown University reaches agreement with Trump administration to restore funding
- Pediatric cancer five-year survival rate has increased dramatically, AACR says in inaugural Pediatric Cancer Progress Report
- Antonio Wolff, Mikala Egeblad named co-directors of Johns Hopkins Kimmel Cancer Center Breast and Gynecologic Cancer Program
- John Byrd brings blood cancer expertise to solid tumor, immunology powerhouse at UPMC














